Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: From the Master Agreement

"11.12 Specific Performance. The parties hereby acknowledge and agree that the failure of any party to perform its agreements and covenants hereunder, including its failure to take all actions as are necessary on its part to consummate the agreements contemplated hereby, will cause irreparable injury to the other party, for which damages, even if available, will not be an adequate remedy. Accordingly, each party hereby consents to the issuance of injunctive relief without bond by any court of competent jurisdiction to compel performance of such party's obligations and to the granting by any court of the remedy of specific performance of its obligations hereunder."

This is a phrase I have used several times over recent years regarding the efforts (or lack thereof) of TPL/Alliancense/Leckrone to aggressively pursue MMP business.
So why is it that neither PTSC nor Moore have sought to invoke this clause given the dearth of MMP licenses over recent months?

Share
New Message
Please login to post a reply